Navigation Links
CuraGen Reports Second Quarter 2009 Financial Results
Date:7/31/2009

liability exposure; uncertainty of additional funding; CuraGen's history of incurring losses and the uncertainty of achieving profitability; reliance on research collaborations and strategic alliances; competition; patent infringement claims against CuraGen's products, processes and technologies; CuraGen's ability to protect its patents and proprietary rights; and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred in the section entitled "Risk Factors" in CuraGen's Annual Report on Form 10-K for the year ended December 31, 2008 and subsequent Quarterly Reports on Form 10-Q , in each case filed with the Securities and Exchange Commission, as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligation to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Additional Information About the Celldex-CuraGen Merger and Where to Find It

In connection with the proposed merger, Celldex and CuraGen intend to file relevant materials with the SEC, including a definitive joint proxy statement/prospectus (the "Joint Proxy Statement/Prospectus"). CuraGen and Celldex have already filed a preliminary joint proxy statement/prospectus with the SEC on June 26, 2009. This joint proxy statement/prospectus is only a preliminary version of the Joint Proxy Statement/Prospectus and should not be relied upon. INVESTORS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE BECAUSE
'/>"/>

SOURCE CuraGen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
2. CuraGen Reports Third Quarter 2008 Financial Results
3. CuraGen Repurchases $50.9 Million of 2011 Convertible Debt for $43.2 Million
4. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
5. CuraGen to Present at the BIO CEO & Investor Conference
6. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
7. CuraGen Corporation Receives Notification from NASDAQ
8. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
9. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
10. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
11. CuraGen Appoints Clinical Oncologist as VP of Medical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... oxide ceramics have potential uses as ferroelectrics, fast ... nuclear waste, generating a great deal of scientific ... these blended materials. , "The interfaces separating the ... radiation properties of the material as a whole," ... researcher on the project. "It is in the ...
(Date:9/23/2014)... 2014 Erlab , the expert ... 1968 and Burdinola, supplier of laboratory furniture solutions, announce ... fume hood. , By integrating Erlab’s ... will now offer an innovative solution utilizing the patented ... chemicals, best-in-class detection technology, and communication for security and ...
(Date:9/23/2014)... CA (PRWEB) September 23, 2014 For the ... Inc. 500|5000 list of the fastest-growing companies. , ... been acknowledged yet again by Inc. Magazine,” ExakTime CEO Tony ... 5000 list by posting a three-year growth rate of 61 ... in that time by more than 40 percent. , Pappas ...
(Date:9/23/2014)... Sept. 23, 2014  Age Defying Dermatology ® , ... has become one of the first clinics in the ... aesthetic laser for tattoo removal. The treatment safely and ... "For years, tattoo removal has been a lengthy, painful, ... "This is an opportunity to erase tattoo pigment more ...
Breaking Biology Technology:Los Alamos researchers uncover properties in nanocomposite oxide ceramics for reactor fuel 2Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2ExakTime Makes Inc. 5000 List for the Fifth Time 2Age Defy Now Offers World's Most Advanced Technology for Tattoo Removal 2
... screening initiative launches in Atlanta and continues for 90 days;, ... in 13 cities ... across the country, ... specialty biopharmaceutical company, today,announced the launch of a 13-city mobile screening ...
... to Impact Lung Cancer Care, ST. LOUIS, ... start-up company, has secured $4.75M in venture capital ... delivery system for minimally,invasive biopsy and ablation of ... was joined by Advantage Capital Partners and existing ...
... EuroPCR08 will highlight choice of different modalities ... available on single integrated imaging platform., SAN DIEGO, ... VOLC ), a leading manufacturer and developer of,intravascular ultrasound ... designed to enhance the diagnosis and,treatment of coronary and ...
Cached Biology Technology:Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 2Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 3Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 4Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5Veran Medical Technologies Secures $4.75M in First Institutional Funding 2Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System 2Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System 3Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System 4
(Date:9/23/2014)... has domesticated animals, selecting the best traits possible ... an intriguing animal to examine adaptation to climate ... selected breeding and a wealth of livestock genome-wide ... study that combined molecular and environmental data, professor ... genes under environmental selection from domesticated sheep breeds. ...
(Date:9/23/2014)... at the University of Wisconsin-Madison and the Morgridge Institute ... to screen for neural toxins, helping flag chemicals that ... Health (NIH) announced today that the UW-Madison and Morgridge ... the promising work as part of the Tissue Chip ... $7 million over the three-year project. , The ...
(Date:9/23/2014)... new tissues during the healing process, cells must ... years, scientists believed this communication happened primarily through ... and the University of Pittsburgh have found that ... if not more crucial. The findings, published in ... the National Academy of Sciences , could lead ...
Breaking Biology News(10 mins):Being sheepish about climate adaptation 2UW-Madison team developing 'tissue chip' to screen neurological toxins 2UW-Madison team developing 'tissue chip' to screen neurological toxins 3The mechanics of tissue growth 2
... anything they want and never gain a pound, while others ... You may be seeing things correctly after all. According ... Genetics ( http://www.genetics.org ), this may have a biological ... with diet, rather than diet alone, are the main cause ...
... (CLOTS)an intensive five-day course offered by the Society ... interventional radiologists, neurointerventionalists, vascular neurologists and fellows-in-training with ... discuss all aspects of acute stroke management. ... in the United States, with about 600,000 new ...
... Just as cooking helps people digest food, pretreating polycarbonate ... of its bisphenol A (BPA) content may be ... eco-friendly way, scientists have found. Their new study is ... Mukesh Doble and Trishul Artham note that manufacturers produce ...
Cached Biology News:Why fad diets work well for some, but not others 2Explore stroke care with Society of Interventional Radiology's CLOTS 2
Mouse monoclonal antibody raised against a full length recombinant SNAPC5. NCBI Entrez Gene ID = SNAPC5...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
Mouse monoclonal antibody raised against a partial recombinant PRKG1. NCBI Entrez Gene ID = PRKG1...
Biology Products: